human
papilloma
viruslik
particl
hpv
vlp
serv
basi
current
licens
vaccin
hpv
previous
shown
encapsid
dna
express
model
antigen
respiratori
syncyti
viru
rsv
hpv
pseudovirion
psv
immunogen
deliv
intravagin
hpv
capsid
confer
tropism
basal
epithelium
repres
attract
carrier
vaccin
target
skin
use
microneedl
studi
ask
whether
vlp
administ
microneedl
could
induc
protect
immun
respons
whether
psvencapsid
plasmid
deliv
microneedl
could
elicit
immun
respons
hpv
antigen
deliv
transgen
mice
immun
vlp
coat
microneedl
gener
robust
neutral
antibodi
respons
protect
challeng
microneedl
array
coat
protein
gene
rsv
test
dosedepend
hpv
fspecif
antibodi
respons
detect
postimmun
tcell
respons
detect
post
rsv
challeng
respect
psvf
immun
mice
fulli
protect
challeng
psv
reduc
rsv
viral
load
lung
nose
upon
intranas
rsv
challeng
summari
psvencapsid
dna
deliv
microneedl
induc
neutral
antibodi
respons
hpv
prime
antibodi
tcell
respons
rsv
antigen
encod
encapsid
plasmid
although
immunogen
dna
compon
dose
respons
threshold
hpvspecif
immun
robust
taken
togeth
data
suggest
microneedl
deliveri
lyophil
hpv
psv
could
provid
practic
thermost
combin
vaccin
approach
could
develop
clinic
evalu
despit
decad
vaccin
develop
infecti
diseas
continu
major
caus
mortal
much
world
roadblock
global
vaccin
program
includ
remot
region
prohibit
cost
good
deliveri
use
needl
wast
dispos
coldchain
requir
crowd
vaccin
schedul
solut
mani
problem
involv
develop
effici
vaccin
stabl
ambient
temperatur
appli
needlefre
minim
wast
combin
vaccin
antigen
reduc
number
inocul
present
case
skintarget
freezedri
formul
combin
human
papillomaviru
hpv
pseudoviru
psv
vaccin
compos
capsid
protein
plasmid
express
respiratori
syncyti
viru
rsv
antigen
deliveri
skin
use
microneedl
pose
attract
mean
immun
skin
potent
site
immun
induct
due
resid
langerhan
cell
dermal
dendrit
cell
pois
initi
immun
respons
protect
host
skin
rich
antigen
present
cell
apc
induct
site
may
requir
rel
low
antigen
dose
lower
requir
adjuv
microneedl
patch
attract
mechan
deliv
biolog
skin
simpli
painlessli
appli
skin
vaccin
drug
deliveri
purpos
microneedl
capabl
effect
deliv
protein
virus
nucleic
acid
low
dose
engin
stabl
strong
dissolv
highli
reproduc
nake
dna
influenza
hpv
viruslik
particl
vlp
demonstr
elicit
b
tcell
immun
respons
administr
skin
use
microneedl
addit
use
dissolv
microneedl
replicationdefect
adenovir
vector
live
measl
viru
vaccin
success
administ
induc
cell
antibodi
respons
hpv
often
primari
etiolog
agent
respons
cervic
cancer
cervic
cancer
rate
develop
region
drop
due
implement
screen
program
rank
second
lead
caus
cancer
death
lessdevelop
region
program
avail
addit
cervic
cancer
hpv
also
associ
head
neck
cancer
well
sever
anogenit
cancer
despit
recent
advent
commerci
prophylact
hpv
vlpbase
vaccin
target
major
highrisk
cancercaus
type
high
cost
product
requir
refriger
make
vaccin
inaccess
individu
low
resourc
set
demonstr
greatest
need
vaccin
rsv
frequent
caus
lower
respiratori
tract
infect
requir
medic
care
children
year
age
yet
prophylact
vaccin
avail
howev
monoclon
antibodi
palivizumab
specif
rsv
fusion
protein
f
licens
prophylaxi
infant
high
risk
seriou
diseas
rsv
f
rel
conserv
across
subtyp
crossneutr
antibodi
discov
make
attract
target
antigen
vaccin
develop
mani
difficult
viru
target
yet
vaccin
solut
may
necessari
induc
cell
respons
addit
neutral
antibodi
respons
achiev
immun
safe
prevent
infect
order
elicit
complex
immun
respons
genebas
immun
appeal
intracellular
antigen
product
result
protein
authent
structur
process
mhc
class
ii
present
pathway
lead
full
complement
cellular
humor
immun
respons
previous
report
hpv
psv
contain
capsid
protein
encapsid
plasmid
deliv
gene
encod
viral
antigen
mucos
tissu
success
elicit
band
tcell
respons
preced
exist
microneedlemedi
deliveri
plasmid
dna
skin
result
express
encod
report
gene
vaccin
antigen
combin
recent
work
suggest
capsid
proteinbas
hpv
vlp
vaccin
gardasil
deliv
skin
microneedl
elicit
neutral
antibodi
nab
indic
hpv
psv
may
amen
deliveri
method
retain
function
show
hpv
psv
deliv
skin
use
microneedl
induc
immun
respons
hpv
capsid
antigen
deliv
encapsid
transgen
absenc
adjuv
use
hpv
deliveri
vehicl
plasmid
encod
vaccin
antigen
use
microneedl
may
therefor
provid
safe
effect
platform
develop
combin
vaccin
easili
deliv
may
much
lower
requir
mainten
cold
chain
current
avail
hpv
vaccin
empti
vlp
green
fluoresc
protein
luciferas
f
protein
express
psv
prepar
previous
describ
use
transfect
system
purifi
densiti
ultracentrifug
use
optiprep
sigma
st
loui
mo
usa
infecti
unit
determin
titrat
prepar
cell
rsv
fusion
protein
f
gene
codonmodifi
base
consensu
sequenc
f
introduc
express
vector
sequenc
found
http
homeccrcancergovlco
targethtm
microneedl
array
consist
row
five
microneedl
fabric
stainless
steel
sheet
triniti
brand
industri
ss
thick
atlanta
ga
usa
wet
etch
coat
solut
compos
wv
carboxymethylcellulos
sodium
salt
low
viscos
usp
grade
carbom
san
diego
ca
usa
trehalos
wv
sigma
st
loui
mo
usa
wv
lutrol
nf
basf
mt
oliv
nj
usa
vaccin
increas
coat
amount
hpvrsv
vaccin
concentr
freez
dri
reconstitut
coat
formul
vari
concentr
describ
experi
dip
coat
procedur
perform
use
special
design
apparatu
base
method
describ
previous
apparatu
chamber
coat
solut
microneedl
holder
attach
motor
linear
stage
newmark
system
rancho
santa
margarita
ca
usa
allow
microneedl
array
move
two
dimens
micromet
accuraci
coat
perform
automat
dip
process
monitor
video
camera
attach
comput
coat
procedur
repeat
time
build
suffici
thick
film
needl
allow
dri
room
temperatur
humid
coat
cycl
overnight
use
vivo
amount
coat
vaccin
consist
within
batch
within
accuraci
fig
anim
work
approv
nih
iacuc
femal
balbc
mice
jackson
laboratori
bar
harbor
usa
hous
niaid
vrc
nci
anim
care
facil
pathogenfre
condit
maintain
standard
rodent
chow
water
suppli
ad
libitum
upon
complet
studi
anim
human
euthan
carbon
dioxid
accord
current
iacucapprov
document
balbc
mice
use
studi
assess
hpv
immun
rsv
f
protein
respons
mice
use
rsv
studi
order
use
optim
number
tetram
reagent
avail
hair
remov
back
anim
use
chemic
depilatori
solut
nair
church
dwight
compani
princeton
nj
usa
h
prior
microneedl
administr
microneedl
place
min
skin
back
shoulder
anesthet
mice
hpv
immunogen
studi
anim
receiv
three
immun
three
week
apart
three
week
follow
final
dose
sera
acquir
anim
cervicovagin
challeng
iu
luc
psv
determin
protect
infect
measur
skin
express
luciferas
psv
deliveri
anim
receiv
singl
treatment
either
microneedl
array
iuarray
bifurc
needl
punctur
needl
scratch
scratch
top
bottom
left
right
follow
addit
iu
prepar
psv
luciferas
detect
day
thru
post
hpv
administr
intraperiton
deliv
luciferas
substrat
dluciferin
potassium
salt
mgml
perkin
elmer
waltham
usa
wait
min
appli
substrat
local
skin
min
imag
acquir
ivi
perkin
elmer
waltham
min
medium
bin
standard
region
interest
creat
around
posit
signal
photon
measur
use
live
imag
softwar
perkin
elmer
psv
studi
anim
receiv
three
immun
cervicovagin
challeng
psv
describ
four
week
hpv
challeng
seven
week
last
microneedl
immun
anim
intranas
challeng
rsv
psv
studi
anim
prime
hpv
four
week
either
challeng
rsv
boost
intramuscularli
im
pfu
rsv
challeng
studi
consist
challeng
anim
pfu
rsv
intranas
evalu
protect
previous
report
bronchoalveolar
lavag
perform
previous
describ
except
bsa
pb
use
follow
bronchoalveolar
lavag
procedur
nasal
wash
perform
insert
endotrach
tube
incis
trachea
nasopharynx
nasopharynx
flush
ml
pb
bsa
collect
wash
fluid
nostril
detail
protocol
hpv
neutral
assay
found
http
homeccrcanc
govlconeutralizationassayhtm
describ
pastrana
et
al
briefli
psv
express
secret
alkalin
phosphatas
coincub
serial
dilut
sera
h
ice
sampl
place
onto
preplat
cell
incub
h
time
supernat
react
substrat
great
escap
seap
chemiluminesc
kit
clonetech
mountain
view
ca
usa
signal
detect
polarstar
optima
plate
reader
bmg
cari
nc
usa
serum
titer
calcul
use
averag
well
noantibodi
control
repres
seap
activ
serum
titer
defin
reciproc
valu
highest
dilut
hpvseap
psv
activ
reduc
calcul
inhibit
curv
gener
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
usa
measur
f
proteinspecif
antibodi
respons
kinet
elisa
rsv
f
protein
purifi
virusinfect
cell
dilut
carbon
buffer
ph
coat
overnight
flatbottom
elisa
plate
nunc
rochest
ny
usa
concentr
ng
per
well
plate
wash
four
time
wash
buffer
pb
use
autom
plate
washer
biotek
instrument
winooski
vt
usa
incub
block
buffer
bsa
pb
h
dilut
test
sampl
posit
control
ad
well
triplic
two
coat
well
one
uncoat
well
plate
incub
h
wash
incub
h
hrpconjug
goat
antimous
hrpconjug
goat
hrpconjug
rabbit
antimous
igg
igm
jackson
immunoresearch
laboratori
hrpconjug
goat
antimous
iga
southern
biotech
birmingham
al
usa
plate
wash
wash
buffer
four
time
follow
distil
water
volum
super
aquablu
elisa
substrat
ebiosci
san
diego
ca
usa
ad
well
plate
read
immedi
use
dynex
technolog
micropl
reader
chantilli
va
usa
rate
color
chang
mod
min
read
wavelength
nm
everi
min
plate
shaken
measur
mean
mod
min
read
duplic
well
calcul
background
mod
min
subtract
correspond
well
perform
previous
describ
graham
et
al
briefli
left
lung
remov
steril
condit
entir
nose
excis
en
block
place
emem
quickfrozen
alcoholdri
ice
bath
store
quick
thaw
tissu
kept
chill
individu
sampl
ground
use
gentlemac
machin
miltenyi
biotech
bergisch
gladbach
germani
program
lung
clarifi
tissu
supernat
inocul
onto
confluent
cell
monolay
triplic
overlaid
methylcellulos
emem
incub
day
monolay
fix
buffer
formalin
stain
hematoxylin
eosin
plaqu
count
express
plaqu
form
unit
pfu
per
gram
lung
tissu
pfu
per
nose
whole
blood
lyse
ml
ack
lyse
buffer
qualiti
biolog
gaithersburg
md
usa
min
sampl
wash
ml
pb
centrifug
x
g
min
lyse
wash
repeat
three
time
cell
pellet
devoid
visibl
amount
rbc
final
remov
supernat
sampl
stain
accord
protocol
surfac
tetram
stain
describ
lymphocyt
isol
right
lung
ficolit
atlanta
biolog
atlanta
ga
usa
tetramerstain
k
ia
b
antibodi
analyz
ninecolor
flow
cytometri
previous
describ
use
vivid
life
technolog
grand
island
ny
usa
stain
exclud
dead
cell
gate
strategi
previous
describ
flow
jo
version
softwar
tree
star
ashland
usa
use
analyz
data
data
analyz
oneway
statist
analysi
varianc
pairwis
comparison
made
use
holmsidak
dunn
method
student
ttest
statist
test
perform
use
sigmastat
window
systat
softwar
san
jose
ca
usa
graphpad
prism
la
jolla
ca
usa
plot
gener
excel
microsoft
redmond
wa
usa
graphpad
prism
test
feasibl
gener
protect
immun
hpv
infect
use
microneedl
compar
intramuscular
inject
microneedl
deliveri
vlp
addit
intramuscular
control
use
vlp
rins
microneedl
vortex
tube
contain
steril
pb
includ
order
ensur
conformationdepend
vlp
epitop
induc
neutral
antibodi
compromis
freez
dri
microneedl
coat
process
vlp
immun
perform
high
dose
low
dose
absenc
adjuv
anim
immun
three
time
three
week
apart
three
week
follow
final
immun
sera
collect
measur
neutral
antibodi
nab
titer
anim
intravagin
challeng
psv
mean
determin
efficaci
vivo
protect
dose
vlp
vaccin
use
microneedl
im
needl
syring
inject
either
unprocess
vaccin
vaccin
elut
microneedl
gener
similar
level
nab
fig
dose
antibodi
titer
im
inject
group
similar
significantli
higher
dose
group
anim
receiv
dose
coat
onto
microneedl
display
lower
neutral
titer
compar
group
like
attribut
difficulti
administ
thickli
coat
microneedl
anim
regardless
vaccin
rout
dose
vaccineinduc
nab
highli
similarli
effect
vivo
demonstr
protect
cervicovagin
challeng
iu
psv
fig
note
one
anim
microneedl
group
complet
protect
challeng
anim
one
two
undetect
level
nab
except
microneedl
group
nab
titer
similar
among
group
indic
immunogen
vlp
remain
unaffect
microneedl
coat
applic
process
dose
respons
signifi
even
antigen
antibodi
respons
follow
microneedl
deliveri
equival
im
immun
one
log
higher
dose
microneedl
deliveri
compar
intramuscular
deliveri
induc
nab
respons
hpv
presenc
encapsid
dna
interfer
hpv
immunogen
hpv
psv
appli
microneedl
vivo
hpv
psvmediat
gene
deliveri
requir
hpv
major
minor
protein
current
hpv
vaccin
formul
contain
vlp
therefor
import
determin
whether
hpv
neutral
immunogen
advers
affect
presenc
encapsid
dna
microneedl
first
coat
psv
prepar
encapsid
plasmid
encod
rsv
fusion
protein
psv
yield
approxim
iu
psvarray
microneedl
rins
pb
content
measur
western
blot
determin
ng
fig
vlp
empti
vlp
coat
onto
microneedl
achiev
similar
concentr
per
array
anim
immun
ng
ng
ng
microneedl
array
three
time
three
week
apart
three
week
follow
final
immun
sera
collect
anim
cervicovagin
challeng
psv
measur
protect
high
level
nab
detect
group
test
regardless
dose
presenc
dna
fig
dose
respons
note
three
condit
examin
statist
signific
drop
nab
level
observ
anim
receiv
empti
particl
compar
psv
immun
anim
howev
mice
complet
protect
intravagin
challeng
iu
fig
differ
antibodi
elicit
may
attribut
presenc
dna
pseudoviru
act
stabil
particl
act
adjuv
overcom
decreas
titer
attribut
presenc
collect
data
indic
induct
hpv
neutral
antibodi
diminish
hpv
capsid
configur
use
gene
deliveri
system
previous
demonstr
deliv
mucos
hpv
psv
effici
vector
genebas
immun
iu
pseudoviru
typic
deliv
approxim
plasmid
dna
prior
test
psvbase
genet
immun
microneedl
first
valid
freezedri
particl
microneedl
array
coat
procedur
interfer
abil
psv
deliv
plasmid
epitheli
cell
two
week
room
temperatur
storag
follow
rehydr
pb
lyophil
luciferaseexpress
psv
prove
equal
effect
gene
deliveri
compar
previous
frozen
particl
use
vivo
vagin
challeng
model
fig
green
fluoresc
protein
particl
rins
microneedl
capabl
deliv
plasmid
vitro
indic
transduct
gfp
express
cell
fig
addit
effici
vivo
particl
deliveri
examin
insert
psvcoat
microneedl
mice
variabl
length
time
measur
amount
particl
remain
array
particl
remain
microneedl
inocul
data
shown
longer
inocul
time
point
increas
effici
deliveri
evalu
vivo
gene
deliveri
skin
psvcoat
microneedl
array
approxim
iu
psvarray
use
inocul
anim
min
dose
approxim
iu
iu
iu
microneedl
array
respect
uncoat
microneedl
bifurc
needl
punctur
needl
scrape
horizont
vertic
scratch
serv
control
begin
h
psv
administr
continu
daili
seven
day
anim
imag
luminesc
signal
indic
success
deliveri
express
luciferas
gene
luminesc
signal
could
detect
background
psv
condit
test
transient
kinet
luciferas
express
use
method
similar
previous
observ
vagin
challeng
model
anim
inocul
microneedl
signal
peak
two
day
postadministr
level
much
higher
background
fig
data
indic
dose
respons
detect
hpv
psv
coat
onto
microneedl
capabl
deliv
gene
vivo
skin
blood
collect
anim
one
month
hpv
administr
follow
cervicovagin
challeng
psv
low
level
ab
detect
group
except
uncoat
microneedl
scrape
group
data
shown
vivo
protect
hpv
challeng
observ
two
group
fig
data
signifi
even
singl
administr
psvcoat
microneedl
capabl
elicit
steril
immun
hpv
mmunogen
retain
inclus
dna
use
hpv
psv
anim
receiv
one
three
variat
particl
empti
particl
encapsid
rsv
f
protein
express
plasmid
psv
approxim
ng
hpv
equival
coat
onto
microneedl
array
mn
array
mice
receiv
either
microneedl
array
control
arm
receiv
microneedl
coat
coat
buffer
anim
immun
three
time
three
week
apart
three
week
last
immun
serum
drawn
mice
cervicovagin
challeng
iu
nab
detect
group
dose
induct
rsv
fspecif
antibodi
hpv
psvencapsid
dna
deliv
microneedl
sera
acquir
day
hpv
challeng
anim
immun
psv
describ
evalu
rsv
fspecif
antibodi
kinet
elisa
mice
receiv
highest
dose
microneedl
array
fspecif
antibodi
wherea
lower
dose
induct
antibodi
respons
inconsist
fig
seven
week
last
immun
one
month
hpv
challeng
anim
challeng
rsv
day
five
anim
euthan
rsv
quantifi
lung
nose
fig
signific
reduct
rsv
pfu
observ
lung
p
nose
p
anim
immun
microneedl
array
coat
psv
evalu
tcell
respons
induc
hpv
psvencapsid
plasmid
deliv
microneedl
immun
mice
psv
previous
shown
immunogen
deliv
intravagin
rsv
use
model
antigen
evalu
cellinduc
immun
mice
microneedl
coat
group
consist
microneedl
array
microneedl
array
antibodi
could
detect
day
indic
inde
particl
success
administ
data
shown
report
dna
vaccin
antigenspecif
cell
often
undetect
prime
therefor
boost
viral
challeng
requir
assess
qualiti
prime
cell
respons
one
month
microneedl
immun
anim
divid
two
group
one
challeng
rsv
boost
lowdos
pfu
recombin
adenoviru
serotyp
vector
im
epitopespecif
tcell
measur
lung
day
postrsv
challeng
group
immun
microneedl
array
demonstr
higher
increas
tcell
signific
increas
tcell
respons
p
baselin
challeng
fig
tetram
respons
measur
blood
fourteen
day
boost
significantli
higher
respons
p
compar
hpvluc
immun
control
observ
anim
immun
microneedl
array
fig
data
herein
describ
use
hpv
psv
vaccin
deliveri
vehicl
combin
vaccin
strategi
psv
resist
freez
dri
lyophil
coat
onto
microneedl
array
retain
conformationdepend
epitop
requir
induc
neutral
antibodi
abil
transduc
gene
antigen
find
support
feasibl
use
microneedlebas
vaccin
hpv
vlp
psv
use
microneedl
could
elimin
need
typic
needl
inject
provid
simpler
less
pain
safer
potenti
costeffect
approach
vaccin
elimin
need
coldchain
transport
storag
respons
observ
data
report
reciproc
dilut
pseudoviru
neutral
compar
posit
control
well
b
protect
challeng
observ
group
measur
vivo
bioluminesc
challeng
psv
group
challeng
order
serv
neg
control
group
luminesc
data
report
averag
radianc
n
p
p
strong
neutral
immun
gener
hpv
infect
singl
dose
approxim
ng
hpv
protein
applic
vaccin
within
dermal
epiderm
layer
may
effect
low
dose
due
part
enrich
sentinel
antigen
present
cell
apc
constantli
survey
tissu
foreign
antigen
langerhan
cell
dermal
dendrit
cell
potent
apc
directli
target
use
microneedl
deliveri
skin
cell
repres
continu
replenish
popul
immun
stimul
activ
travel
drain
lymph
node
present
antigen
cell
known
hpv
particl
taken
process
studi
howev
hpv
may
especi
effect
suit
microneedl
deliveri
local
viral
particl
within
epithelium
context
display
natur
tropism
basal
cell
stabil
data
immunogen
data
present
use
psv
combin
data
corbett
et
al
suggest
hpv
vaccin
administr
microneedl
array
consid
clinic
evalu
immun
dna
simplest
form
genebas
vaccin
deliveri
immunogen
nake
dna
improv
use
devic
biojector
approach
includ
electropor
pursu
improv
potenc
current
much
effort
focus
im
deliveri
directli
induc
prime
signific
tcell
antibodi
respons
previous
demonstr
deliv
genit
mucosa
equival
immun
respons
could
elicit
nake
dna
compar
lower
dose
dna
encapsid
within
hpv
psv
nonrepl
vector
hpv
psv
candid
vaccin
lend
highli
effici
deliveri
nucleic
acid
cell
skin
oppos
mechan
approach
use
ballist
forc
electr
disrupt
improv
transduct
effici
hpv
psv
encapsid
provid
biolog
solut
facilit
dna
deliveri
target
microneedl
deliveri
basal
epithelium
base
hpv
tropism
current
approach
potenti
facilit
dna
deliveri
gene
express
vaccin
antigen
studi
show
microneedl
deliveri
hpv
psv
skin
elicit
antibodi
cell
respons
rsv
antigen
encod
plasmid
dna
encapsid
within
psv
respons
rel
modest
dose
respons
observ
anim
receiv
highest
dosag
immun
respons
gener
capabl
reduc
viral
replic
coadminist
hpv
psv
express
immun
modifi
could
potenti
enhanc
band
tcell
respons
express
modifi
would
transient
thu
diminish
safeti
concern
associ
advers
effect
longterm
express
overexpress
immun
modifi
optim
vaccin
strategi
primari
focu
microneedl
design
payload
order
deliv
higher
dose
dna
easili
achiev
increas
number
microneedl
patch
microneedl
array
use
studi
small
limit
abil
deliv
higher
dose
vaccin
compar
data
report
averag
radianc
n
b
microneedl
test
articl
microneedl
coat
standard
coat
formul
well
coat
formul
lack
cmc
rt
room
temperatur
green
fluoresc
protein
coat
onto
microneedl
coat
microneedl
incub
monolay
cell
cell
examin
flow
cytometri
hour
later
determin
percentag
infect
cell
c
mice
inocul
microneedl
deliv
approxim
iu
mn
iu
mn
iu
mn
psv
encapsid
firefli
luciferas
report
plasmid
uncoat
microneedl
uncoat
mn
contain
psv
use
neg
control
anim
receiv
bifurc
needl
treatment
bf
needl
needl
scratch
treatment
scrape
iu
prepar
ad
skin
immedi
skin
traumat
mice
imag
daili
luciferas
signal
averag
radianc
shown
individu
anim
imag
valu
averag
radianc
depict
signal
observ
anim
day
peak
luciferas
express
n
recent
develop
technolog
patch
hollow
microneedl
also
dissolv
microneedl
patch
compos
watersolubl
excipi
repres
perhap
promis
altern
technolog
examin
futur
studi
studi
address
three
central
issu
associ
vaccin
use
microneedl
first
found
lyophil
hpv
vlp
hpv
psv
could
appli
microneedl
remain
antigen
stabl
room
temperatur
second
vaccin
hpv
vlp
gener
robust
protect
immun
respons
support
develop
microneedl
deliveri
hpv
vaccin
place
im
inject
third
vaccin
hpv
psv
gener
strong
protect
immun
respons
hpv
induc
dosedepend
band
tcell
respons
rsv
antigen
encod
encapsid
dna
data
support
futur
develop
combin
vaccin
strategi
hpv
psv
vector
gener
immun
hpv
antigen
express
encapsid
plasmid
dna
conclud
vaccin
microneedl
may
ideal
method
hpv
vaccin
vlp
may
allow
futur
develop
hpv
psvencapsid
dna
vaccin
concept
would
result
immun
hpv
addit
antigen
encod
dna
fig
one
month
administr
psv
either
scrape
disrupt
bifurc
needl
microneedl
iu
administ
anim
imag
later
luciferas
activ
psv
group
challeng
order
serv
neg
control
group
luminesc
data
report
averag
radianc
n
tif
